Cyclo Therapeutics (Cyclo Therapeutics) ROCE % : -1,202.24% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cyclo Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -1,202.24%.

Cyclo Therapeutics ROCE % Historical Data

The historical data trend for Cyclo Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics ROCE % Chart

Cyclo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-752.26

-156.00

-108.90

-190.11

-727.24

Cyclo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-626.82	-12,101.51	-	-	-1,202.24

Cyclo Therapeutics ROCE % Calculation

Cyclo Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-20.05	/	( ( (4.215 - 3.481)	+	(13.248 - 8.468) )	/ 2 )
	=	-20.05	/	( (0.734	+	4.78)	/ 2 )
	=	-20.05	/	2.757
	=	-727.24 %

Cyclo Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-22.572	/	( ( (5.597 - 6.622)	+	(13.248 - 8.468) )	/ 2 )
	=	-22.572	/	( ( -1.025	+	4.78 )	/ 2 )
	=	-22.572	/	1.8775
	=	-1,202.24 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Cyclo Therapeutics (NAS:CYTHW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cyclo Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTHW) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CYTH:USA

Address

6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653

Website

https://www.cyclodex.com

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.